Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz.
作者信息
Kummer O, Mossdorf E, Battegay M, Elzi L, Bodmer M, Krähenbühl S, Haschke M
出版信息
Gut. 2007 Oct;56(10):1477-8. doi: 10.1136/gut.2007.126144.
Abstract
摘要
相似文献
1
Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz.
Gut. 2007 Oct;56(10):1477-8. doi: 10.1136/gut.2007.126144.
2
[Highly effective and tolerable protease inhibitor. New trump card against HIV].
MMW Fortschr Med. 2003 Jan 16;145(1-2):55.
3
[Atazanavir-induced nephrolithiasis].
Enferm Infecc Microbiol Clin. 2009 Feb;27(2):134-5. doi: 10.1016/j.eimc.2007.12.001. Epub 2009 Feb 25.
4
HIV therapeutics, continued: another HIV protease inhibitor approved.
AIDS Read. 2003 Aug;13(8):355-6.
5
Does atazanavir cause lipodystrophy?
J HIV Ther. 2004 May;9(2):41-4.
6
Atazanavir urolithiasis.
N Engl J Med. 2006 Nov 16;355(20):2158-9. doi: 10.1056/NEJMc061892.
7
Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.
AIDS Res Hum Retroviruses. 2012 Sep;28(9):1015-8. doi: 10.1089/AID.2011.0261. Epub 2012 May 3.
8
[Adverse effects of atazanavir].
Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:41-4. doi: 10.1016/S0213-005X(08)76619-9.
9
The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
Ther Drug Monit. 2013 Feb;35(1):71-7. doi: 10.1097/FTD.0b013e3182791f8c.
10
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S90-7. doi: 10.1086/381444.
引用本文的文献
1
Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up.
AIDS Patient Care STDS. 2013 Jul;27(7):378-86. doi: 10.1089/apc.2013.0009.
2
Individualization of antiretroviral therapy.
Pharmgenomics Pers Med. 2012;5:1-17. doi: 10.2147/PGPM.S15303. Epub 2011 Dec 29.
本文引用的文献
1
Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
Gut. 2007 Aug;56(8):1111-6. doi: 10.1136/gut.2006.106690. Epub 2007 Mar 15.
2
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.
J Pharmacol Exp Ther. 2007 Jan;320(1):72-80. doi: 10.1124/jpet.106.112136. Epub 2006 Oct 13.
3
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
AIDS. 2005 Apr 29;19(7):685-94. doi: 10.1097/01.aids.0000166091.39317.99.
4
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.
AIDS. 2003 Dec 5;17(18):2603-14. doi: 10.1097/00002030-200312050-00007.
5
Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor.
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4150-5. doi: 10.1073/pnas.0438010100. Epub 2003 Mar 18.
6
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.
J Biol Chem. 2002 Jan 25;277(4):2908-15. doi: 10.1074/jbc.M109326200. Epub 2001 Nov 12.
7
Effect of sodium phenobarbital on bilirubin metabolism in an infant with congenital, nonhemolytic, unconjugated hyperbilirubinemia, and kernicterus.
J Clin Invest. 1969 Jan;48(1):42-55. doi: 10.1172/JCI105973.
8
Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity.
Am J Med. 1969 Sep;47(3):395-409. doi: 10.1016/0002-9343(69)90224-1.
Zotero 插件